Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 2
2017 1
2018 1
2019 2
2020 1
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Determinants of Use of Biotherapeutics in sub-Saharan Africa.
Shah R, Dey D, Pietzonka T, Obeng P, Ashiru B, Schiestl M, Cavey A, Nkansah E, Radiere G, Spector J, Scott C. Shah R, et al. Among authors: cavey a. Trends Pharmacol Sci. 2021 Feb;42(2):75-84. doi: 10.1016/j.tips.2020.11.012. Epub 2020 Dec 24. Trends Pharmacol Sci. 2021. PMID: 33358177 Review.
A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.
Coe S, Cossington J, Collett J, Soundy A, Izadi H, Ovington M, Durkin L, Kirsten M, Clegg M, Cavey A, Wade DT, Palace J, DeLuca GC, Chapman K, Harrison JM, Buckingham E, Dawes H. Coe S, et al. Among authors: cavey a. J Neurol Neurosurg Psychiatry. 2019 May;90(5):507-513. doi: 10.1136/jnnp-2018-319496. Epub 2019 Mar 4. J Neurol Neurosurg Psychiatry. 2019. PMID: 30833449 Clinical Trial.
A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS).
Coe S, Collett J, Izadi H, Wade DT, Clegg M, Harrison JM, Buckingham E, Cavey A, DeLuca GC, Palace J, Dawes H. Coe S, et al. Among authors: cavey a. Pilot Feasibility Stud. 2018 Jan 23;4:35. doi: 10.1186/s40814-018-0230-7. eCollection 2018. Pilot Feasibility Stud. 2018. PMID: 29403649 Free PMC article.
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G, Evangelou N, Ford H, Gallagher P, George K, Geraldes Ramos Dias R, Harman P, Hobart J, King T, Linighan R, MacDougall N, Marta M, Mitchell S, Nicholas R, Rog D, Scalfari A, Scolding N, Webb S, White S, Wilton J, Young C, Matthews PM. Dobson R, et al. Among authors: cavey a. Mult Scler Relat Disord. 2022 Jul;63:103894. doi: 10.1016/j.msard.2022.103894. Epub 2022 May 20. Mult Scler Relat Disord. 2022. PMID: 35636271 Free article.
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. Dobson R, et al. Among authors: cavey a. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. BMJ Open. 2021. PMID: 34824113 Free PMC article.
The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
Messina S, Mariano R, Geraldes R, Kim SH, Satukijcha C, Vecchio D, Chua YY, Taylor J, George N, Cavey A, Diaz AR, Reeve S, Everett R, De Luca G, Leite MI, Kim HJ, Palace J. Messina S, et al. Among authors: cavey a. Mult Scler Relat Disord. 2021 Apr;49:102773. doi: 10.1016/j.msard.2021.102773. Epub 2021 Jan 19. Mult Scler Relat Disord. 2021. PMID: 33540279
20 results